Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

Clinical Trial ID NCT03509246

PubWeight™ 0.00^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT03509246

Top papers